Unique ID issued by UMIN | UMIN000050900 |
---|---|
Receipt number | R000058009 |
Scientific Title | Study on psychological changes at ingestion of the test product. |
Date of disclosure of the study information | 2024/04/21 |
Last modified on | 2023/10/11 09:16:24 |
Study on psychological changes at ingestion of the test product.
Study on psychological changes at ingestion of the test product.
Study on psychological changes at ingestion of the test product.
Study on psychological changes at ingestion of the test product.
Japan |
Healthy subjects
Adult |
Others
NO
The relaxing effect of the test beverage will be examined for Japanese men and women between 20 and 35 years of age.
Safety,Efficacy
Psychological evaluation questionnaire
(Secondary outcomes)
Heart rate sensor measurement data.
(Safety evaluation)
Vital signs, physical measurements (body weight, BMI), adverse events.
Interventional
Cross-over
Randomized
Individual
Single blind -investigator(s) and assessor(s) are blinded
Placebo
2
Prevention
Food |
Intake test beverage on the day.
Washout.
Intake placebo beverage on the day.
Intake placebo beverage on the day.
Washout.
Intake test beverage on the day.
20 | years-old | <= |
35 | years-old | >= |
Male and Female
1.Japanese males and females who are between 20 and 35 years of age at the time of written informed consent.
2.Subject with BMI <30kg/m2.
3.Non-smokers. (no smoking in the last year)
4.Subject who has received sufficient explanation of the purpose and content of the research, has the ability to consent, voluntarily volunteered to participate in the examination after understanding it well, and agreed to participate in the examination in writing.
1.Subject receiving medication or outpatient treatment for a serious disease.(Use on a PRN(as needed) basis will be permitted.)
2.Subject receiving exercise or diet therapy under the supervision of a physician.
3.Subject who has currently taking any products (e.g., foods for specified health use, foods with functional claims, dietary supplements or health foods, drugs, quasi-drugs) that can affect the autonomic nervous system, metabolism, or sleep, and are unable to discontinue taking them during the study period.
4.Subject who is attending a hospital due to mental disorders (depression, etc.) or sleep disorders, or who has a history of mental illness in the past.
5.Subject with a history or current illnesses of serious diseases such as heart, liver, kidneys, digestive organs, brain, malignant tumors, immune diseases, diabetes, etc.
6.Subject who has problems with heart rate measurement (thick chest hair, using a pacemaker, rash on the skin (chest), etc.)
7.Heavy drinker.
8.Subject who has difficulty quitting drinking from the day before the test date.
9.Subject who has extremely irregular eating habits, those who work shifts, those who work late at night, etc.
10.Subject who is participating in other clinical trials at the time of obtaining consent, and who plans to participate in other clinical trials within 4 weeks from the end of the study to the start of the main study of the study, or after consenting to participate in the study.
11.Subject who has moved residences, changed jobs, separated from close relatives, or had equivalent events within the last 3 months and thus are likely to be under a great deal of stress, or who may have such an event during the study period.
12.Subject who exercises violently on a daily basis.
13.Subject with severe PMS (premenstrual syndrome) symptoms.
14.Subject who is planning to get pregnant during the test period after the day of informed consent or is currently pregnant and lactating.
54
1st name | Hidemasa |
Middle name | |
Last name | Toya |
HUMA R&D CORP
Clinical Development Department
108-0014
Round Cross Tamachi 9F, 5-31-19 Shiba, Minato-ku, Tokyo, 108-0014 Japan
03-3431-1260
toya@huma-rd.co.jp
1st name | Hidemasa |
Middle name | |
Last name | Toya |
HUMA R&D CORP
Clinical Development Department
108-0014
Round Cross Tamachi 9F, 5-31-19 Shiba, Minato-ku Tokyo, 108-0014 Japan
03-3431-1260
toya@huma-rd.co.jp
HUMA R&D CORP
Asahi Quality & Innovations, Ltd
Profit organization
Ethics Committees of Yoga Allergy Clinic
4-32-16 Yoga, Setagaya-ku, Tokyo, 158-0097 Japan
03-5491-4478
jim@medipharma.co.jp
NO
2024 | Year | 04 | Month | 21 | Day |
Unpublished
54
Completed
2023 | Year | 04 | Month | 12 | Day |
2023 | Year | 04 | Month | 14 | Day |
2023 | Year | 04 | Month | 24 | Day |
2023 | Year | 06 | Month | 15 | Day |
2023 | Year | 06 | Month | 26 | Day |
2023 | Year | 07 | Month | 06 | Day |
2023 | Year | 09 | Month | 30 | Day |
(Exclusion criteria continued)
15.Subject with seasonal (spring) pollinosis or perennial allergic rhinitis.
16.Subject who is allergic to medicines and food.
17.Subject with current or former drug or alcohol dependence.
18.Subject who has constitutionally incapable of drinking alcohol.
19.Subject who unable to comply during the study period.
20.Subject who the investigator has determined that participation in this study is inappropriate.
2023 | Year | 04 | Month | 21 | Day |
2023 | Year | 10 | Month | 11 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000058009
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |